Press Release

Disclosures: Van Haur and Roberson are employees of VitalConnect.
November 23, 2020
1 min read

Cloud-based cardiac monitor for real-time arrhythmia detection launched


Press Release

Disclosures: Van Haur and Roberson are employees of VitalConnect.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

VitalConnect announced the launch of its AI-based continuous remote cardiac monitoring solution for patients who require extended Holter monitoring.

The new system (VitalPatch RTM, VitalConnect) monitors for 21 cardiac arrhythmias, captures data on four key vital signs (heart rate, heart rate variability, respiratory rate and activity) and, in real time, stores patient data on the company’s secure cloud (VitalCloud), where physicians can view the patient’s status at any time, according to a press release.

ECG with stethoscope_Shutterstock
Source: Adobe Stock

“Our VitalPatch RTM combines a state-of-the-art solution to comfortably monitor cardiac patients for arrhythmias while also sending important patient vital signs to the physician,” Peter Van Haur, CEO of VitalConnect, said in the release. “This solution not only offers an advancement in cardiac monitoring technology to the cardiology community, but continues to expand our footprint into health care markets that can benefit from the innovation that VitalConnect brings to patient care.”

In addition, VitalConnect introduced a new diagnostic service (Extended Holter NOW), which generates an interim report after 5 days of monitoring, with the aim of shortening the monitoring period for select patients.

“Our Extended Holter NOW solution benefits physicians through access to real-time and historic patient data, giving more insight into the condition of the patient,” Joseph Roberson, MD, Chief Medical Officer for VitalConnect, said in the release. “Additionally, patients appreciate the ease and comfort of the device and the fact that it has the potential to shorten the time they need to be monitored. We believe this will be a breakthrough technology that truly benefits both cardiologists and their patients.”

VitalConnect will monitor patients’ continuous ECG and physiological data with its new independent diagnostic testing facility, which will consist of nationally certified cardiographic and rhythm analysis technicians. Upon completion of a patient’s monitoring period, prescribing physicians will be provided with a clinically actionable final report.